Global & Public Health (all articles)
[Preprint] Vaccine effectiveness of two and three doses of Pfizer and CoronaVac against COVID-19 in Hong Kong.
25 Mar, 2022 | 09:43h | UTC
Commentary on Twitter
New data from Hong Kong on Coronavac and Pfizer vaccines implicates lack of vaccination and boosters in people of advanced age, not type of vaccine, for extreme fatality rates.
2 doses: Coronavac less protective than Pfizer
3 doses: equivalent VEhttps://t.co/BSOGscPvmc pic.twitter.com/UZqYhN7zP5— Eric Topol (@EricTopol) March 23, 2022
[Preprint] Risk of death following SARS-CoV-2 infection or COVID-19 vaccination in young people in England: a self-controlled case series study.
25 Mar, 2022 | 09:47h | UTC
Commentary on Twitter
Pleased to share our study showing that there is no evidence of an increased risk of death in young people after COVID-19 vaccination in England
Great collaboration with @kamleshkhunti @amibanerjee1 and others not on twitter!https://t.co/EV4xmDWeyB pic.twitter.com/VQy2PtCxeC
— Vahé Nafilyan (@Vnafilyan) March 24, 2022
Review: Tobacco and nicotine use.
25 Mar, 2022 | 08:49h | UTCTobacco and nicotine use – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Tobacco and nicotine use (if the link is paywalled, try this one)
Commentary on Twitter
Get Primed on Tobacco and nicotine use with our NEW PrimeView! FREE to download this week! #smokinghttps://t.co/OYwqtYwWLb pic.twitter.com/11xDdLFTvC
— Nature Reviews Disease Primers (@DiseasePrimers) March 24, 2022
Did the COVID lockdowns work? Here’s what we know two years on.
25 Mar, 2022 | 09:44h | UTCDid the COVID lockdowns work? Here’s what we know two years on – The Conversation
Related:
Study Commentary: Widespread screening catches more cases of depression. But follow-up care still falls far short.
25 Mar, 2022 | 08:34h | UTC
Test-negative, case-control study: effectiveness of the Pfizer vaccine against COVID-19 in adolescents.
24 Mar, 2022 | 09:44h | UTCEffectiveness of BNT162b2 against COVID-19 in adolescents – The Lancet Infectious Diseases
Commentary on Twitter
Our paper on #COVID19 vaccine effectiveness in teenagers (12-17y) is published @TheLancetInfDis. Rapid waning of protection against symptomatic disease, esp with omicron. Vaccines did reduce delta hospitalisations but too early to assess omicron effects
— Shamez Ladhani (@ShamezLadhani) March 23, 2022
RCT: Safety and efficacy of a third dose of the Pfizer Covid-19 vaccine during the Delta wave.
24 Mar, 2022 | 09:46h | UTCSafety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine – New England Journal of Medicine
Commentary on Twitter
A third dose of the BNT162b2 vaccine administered a median of 10.8 months after the second dose provided 95.3% efficacy against Covid-19 as compared with two doses. #COVID19 #IDTwitter https://t.co/IeHOgVhU8a pic.twitter.com/wValXSdyHX
— NEJM (@NEJM) March 23, 2022
M-A: Global prevalence and trends in hypertension and type 2 diabetes mellitus among slum residents.
24 Mar, 2022 | 08:30h | UTC
Higher cigarette taxes could reduce child deaths, first global estimates suggest.
24 Mar, 2022 | 08:25h | UTCNews Release: Higher cigarette taxes reduce child deaths, first global estimates suggest – Imperial College London
Original Study: Cigarette taxation and neonatal and infant mortality: A longitudinal analysis of 159 countries – PLOS Global Public Health
Review: Are we overlooking alcohol use by younger children?
24 Mar, 2022 | 08:21h | UTCAre we overlooking alcohol use by younger children? – BMJ Paediatrics Open
Oxford Covid jab gears up for final act: saving the rest of the world.
23 Mar, 2022 | 10:35h | UTCOxford Covid jab gears up for final act: saving the rest of the world – The Guardian
Collaboration and shared decision-making between patients and clinicians in preventive health care decisions and US Preventive Services Task Force Recommendations.
23 Mar, 2022 | 10:39h | UTC
Systematic Review: Economic evaluation guidelines in low- and middle-income countries.
23 Mar, 2022 | 10:22h | UTC
Global guidelines for emergency general surgery: systematic review and Delphi prioritization process.
23 Mar, 2022 | 09:53h | UTC
New WHO guidelines on the management of tuberculosis in children and adolescents.
22 Mar, 2022 | 09:52h | UTC
RCT: Effect of a physical activity and behavior maintenance program on functional mobility decline in older adults.
22 Mar, 2022 | 09:47h | UTCInvited Commentary: Considerations for maintaining functional mobility in older populations – The Lancet Public Health
Outcomes and safety of history-based screening for medication abortion: a retrospective multicenter cohort study.
22 Mar, 2022 | 08:11h | UTCInvited Commentary: It Is Time to Change the Standard of Medication Abortion – JAMA Internal Medicine (free for a limited period)
Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity.
21 Mar, 2022 | 09:47h | UTC
Commentary on Twitter
Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severityhttps://t.co/iFL1AD4q2l@pvmarkov, @ArisKatzourakis & Stilianakis argue that ongoing rapid antigenic evolution is likely to produce new variants that may escape immunity and be more severe. pic.twitter.com/BddNu5DZaq
— Nature Reviews Microbiology (@NatureRevMicro) March 14, 2022
CDC Report: Effectiveness of mRNA vaccination in preventing COVID-19–associated invasive mechanical ventilation and death in the US.
21 Mar, 2022 | 09:38h | UTCCommentary: Studies show vaccines protect against serious Omicron illness – CIDRAP
Commentary on Twitter
New @CDCMMWR study finds #COVID19 vaccines continued to be highly effective at protecting adults from being put on a ventilator or dying during Omicron. All eligible adults should stay up to date w/ COVID-19 vaccines to protect against severe disease. https://t.co/nLi7B2SLJy pic.twitter.com/4o35Vhjg1K
— CDC (@CDCgov) March 18, 2022
Effectiveness of the Johnson & Johnson vaccine in health-care workers in South Africa in a period when the beta and then the delta SARS-CoV-2 variants of concerns were dominant.
21 Mar, 2022 | 09:43h | UTCInvited Commentary: Sisonke: reaching several goals together – The Lancet
Commentary on Twitter (thread – click for more)
Single-dose Ad26.COV2.S vaccine in healthcare workers in South Africa shows effectiveness against severe #COVID19 outcomes—and against beta and delta variants, study indicates.https://t.co/S13Ia1H8BT pic.twitter.com/XgbXGcT9XR
— The Lancet (@TheLancet) March 19, 2022
More data suggests reduced risks of hospitalization and death due to SARS-CoV-2 Omicron compared to the Delta variant.
18 Mar, 2022 | 09:36h | UTCInvited Commentary: Omicron: fewer adverse outcomes come with new dangers – The Lancet
Commentary on Twitter
NEW—People with SARS-CoV-2 #omicron variant less likely to be admitted to hospital or die compared to those with delta variant, indicates large English study. https://t.co/xZvH5qMRDJ pic.twitter.com/fnn7xMBYDB
— The Lancet (@TheLancet) March 17, 2022
Study on traumatic brain injury highlights global inequality in causes and treatment.
18 Mar, 2022 | 09:37h | UTCNews Release: Largest ever study on traumatic brain injury highlights global inequality in causes and treatment – University of Cambridge
Using absolute risk reduction to guide the equitable distribution of COVID-19 vaccines.
18 Mar, 2022 | 09:28h | UTC
Commentary on Twitter
Using absolute risk reduction to guide the equitable distribution of COVID-19 vaccines – Analysis by Fassler et al.
What's the role of NNV?#OpenAccess
▶️ https://t.co/Bb3HlJDRXz pic.twitter.com/MPxrGNHxum
— BMJ Evidence-Based Medicine (@BMJ_EBM) March 17, 2022
Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.
17 Mar, 2022 | 09:12h | UTCEfficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron – New England Journal of Medicine
Related: [Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.
Effectiveness of the Sputnik V, AstraZeneca, and Sinopharm vaccines for the risk of infection and death due to COVID-19 in people older than 60 years in Argentina.
17 Mar, 2022 | 09:10h | UTCCommentary: Evaluating COVID-19 vaccines in the real world – The Lancet